Der Nephrologe

, Volume 4, Issue 4, pp 346–347

Umstellung von Calcineurininhibitor-basierter Immunsuppression auf Sirolimus nach Nierentransplantation

Auswirkungen auf das Tumorrisiko
Für Sie gelesen
  • 53 Downloads

Conversion from calcineurin-based immunosuppression to sirolimus after kidney transplant

Effect on the risk of cancer

Literatur

  1. 1.
    Guba M, von Breitenbuch P, Steinbauer M et al (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8:128–135CrossRefPubMedGoogle Scholar
  2. 2.
    Stallone G, Schena A, Infante B et al (2005) Sirolimus for Kaposi’s sarcoma in renal-transplant recipients. N Engl J Med 352:1317–1323CrossRefPubMedGoogle Scholar
  3. 3.
    Fijter JW de (2007) Use of proliferation signal inhibitors in non-melanoma skin cancer following renal transplantation. Nephrol Dial Transplant 22 (suppl 1):i23–i26CrossRefPubMedGoogle Scholar
  4. 4.
    Mathew T, Kreis H, Friend P (2004) Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant 18:446–449CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  1. 1.Klinik für Nieren und HochdruckkrankheitenUniversitätsklinikum Schleswig-Holstein, Campus KielKielDeutschland

Personalised recommendations